ADC Therapeutics SA
ZYNLONTA
relapsed or refractory diffuse large B-cell lymphoma
Date
TBD
Approval decision · Date TBD estimated
What's at stake
A final FDA approval decision on ZYNLONTA for relapsed or refractory diffuse large B-cell lymphoma is expected Date TBD.
Primary source
· SEC 8-K
verified 13h ago
“Assuming positive results, a supplemental Biologics License Application (sBLA) submission to the U.S. FDA will follow, with potential compendia inclusion in the first half of 2027 and confirmatory approval in 2L+ DLBCL in mid-2027.”